News ID: 207755
Published: 0839 GMT January 08, 2018

Molecular mechanism behind HIV-associated dementia revealed

Molecular mechanism behind HIV-associated dementia revealed
The interaction between APP (red) and GAG (green) in the cell.

For the first time, scientists have identified and inhibited a molecular process that can lead to neurodegeneration in patients with HIV.

According to, Mojgan Naghavi, PhD, associate professor of Microbiology-Immunology, was senior author on the study, and Qingqing Chai, PhD, a postdoctoral fellow in Naghavi's lab, was the lead author.

Previous studies have found elevated levels of toxic beta-amyloid protein in the brains of patients with human immunodeficiency virus (HIV), causing HIV-associated neurocognitive disorder (HAND).

While combination antiretroviral therapy can greatly slow down HIV progression, up to 50 percent of these patients exhibit milder forms of HAND.

Naghavi said, “Buildup of beta-amyloid is thought to be a major contributor to neurodegeneration in a variety of dementia-associated diseases, especially Alzheimer's, but how and why beta-amyloid is produced in HIV-infected patients and its contribution to HAND was a mystery.

"The HIV virus cannot infect neurons because they don't have the right receptors.

"We've known about elevated beta-amyloid levels for a long time, but nobody knew how or why the protein was overproduced in response to infection."

The first clue came when Naghavi and her colleagues preformed a large-scale assay looking for unusual interactions between cellular proteins and Gag, an important HIV protein.

A number of proteins were shown to bind with Gag, but one stood out — membrane-associated amyloid precursor protein (APP), a protein that can be processed to produce the toxic beta-amyloid protein.

Naghavi said, "We put two and two together: We knew APP is a precursor to beta-amyloid, so we looked for APP and found increased processing of this protein into beta-amyloid in infected macrophages and microglia.

“Macrophages and microglia are two types of non-neuronal brain cells that HIV infect, often functioning as reservoirs of the disease in the brain.”

In those cells, APP interferes with HIV infection, and in response, HIV tries to circumvent that barrier.

Naghavi said, “During infection of a microglia or macrophage cell, HIV's Gag protein promotes processing of APP, reducing resistance to cell takeover, which also has the side-effect of producing toxic beta-amyloid proteins

"By binding to APP, somehow Gag drags it into cell membrane regions called lipid rafts, where there are enzymes that promote processing of APP into beta-amyloid.

"This is the first time we've showed HIV is trying to overcome a block that is induced by APP in microglia and macrophages.

“To reduce buildup of beta-amyloid, the scientists targeted the enzyme that cleaves APP, called gamma secretase.

“A simple inhibitor that blocked APP processing produced dual benefits by inhibiting infection and reducing beta-amyloid production.”

When the drug blocks APP processing, it reduces beta amyloid and increases APP compared to non-drugged models.

This results in the combined benefits of reduced neurodegeneration and sustaining APP's original function of blocking infection.

Naghavi added, "We've opened the door for how these drugs might be used to block both HIV replication and treat HIV-associated dementia.

"It would also be interesting to investigate whether APP affects replication of other neurotropic viruses, for example Zika or Cytomegalovirus."


Security Key:
Captcha refresh
Page Generated in 0/2337 sec